ClinicalTrials.gg
WithdrawnNCT05222165NEWELUpdated Feb 23, 2023

Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations

A Phase 1/2 interventional study of Infigratinib in Advanced Solid Tumor, CNS Tumor and Recurrent WHO Grade II Glioma, sponsored by Helsinn Healthcare SA. Withdrawn at 10 sites in 3 countries. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2023-02-23.

Sponsored by Helsinn Healthcare SA · Phase 1/2, Interventional, and Treatment

Why this study was withdrawn
The company decided to interrupt the development of the drug in all oncological indications

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Oct 2021, registered Jan 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
3 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Central Nervous System Neoplasms with a site in United States — 46 open to participants now, 74 under way, 3 of them phase 3. Central Nervous System Neoplasms · United States.

Enrollment
389th of 399
0 · median 31
Started
2021
with 12 others
Phase 1/2
70 of 547
7 open now
Registered
503rd of 547
by date

Among the 547 studies in Central Nervous System Neoplasms with a site in United States, this one is the 389th largest by enrollment of the 399 interventional ones that give a count, is one of 13 that started in 2021, is one of 70 in phase 1/2, and was the 503rd registered.

Central Nervous System Neoplasms

699 studies on the registry are indexed under Central Nervous System Neoplasms; 66 are open to participants now.

Browse Central Nervous System Neoplasms studies →

Open to participants now

46 of the 547 studies in Central Nervous System Neoplasms with a site in United States are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 57 Central Nervous System Neoplasms studies recruiting now, 35 (61%) set no upper age limit and 19 (33%) stop at 75 or younger; 35 take children under 18; 6 take healthy volunteers.

This study: 3 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Central Nervous System Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The phase 1b study is aimed at determining the pediatric recommended phase 2 dose (RP2D) of Infigratinib.

The phase 2 study will evaluate efficacy and safety of infigratinib.

Read the detailed description

Phase 1b:

Pediatric subjects with advanced solid and CNS tumors or recurrent or progressive Low-Grade Glioma with selected FGFR1-3 alterations will follow a standard dose escalation, in 3 dose levels, to determine the pediatric recommended Phase 2 dose (RP2D) and to assess the safety.

Dose escalation decisions will be assessed through three dose level cohorts.

Phase 2:

To evaluate the efficacy and safety in Pediatric and adult subjects with LGG with selected FGFR1-3 alterations (including subjects who received infigratinib at the RP2D).

03

Conditions studied

  • Advanced Solid Tumor
  • CNS Tumor
  • Recurrent WHO Grade II Glioma

Keywords

  • Low-Grade Glioma
  • FGFR1-3 Mutation or fusion/rearrangements
  • FGFR1-3 Fusion
  • FGFR1-3 Rearrangements
  • Advanced Solid Tumor
  • CNS Tumor
04

Who can participate

Ages eligible
3 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Phase 1b:

  • Subject must be ≥ 3 to \<18 years of age at the Screening visit.
  • Confirmed diagnosis of one of the following:

    1. LGG (WHO Grade I or II glioma) based on histology, molecular, and clinical criteria concordant with the WHO Grading of Tumors of the Central Nervous System, including glial or mixed neuronal-glial tumor
    2. Histologically/ confirmed CNS tumor (other than LGG).
    3. Histologically/cytologically confirmed advanced solid tumor.
  • Disease is recurrent or progressive after standard therapy (at least 1 prior standard therapy appropriate for tumor type and stage of disease unless available standard therapies are considered inadequate for the subject).

Phase 2 at screening:

  • Diagnosis of recurrent or progressive (at least 1 prior standard therapy) LGG (WHO Grade I or II glioma), including glial or mixed neuronal-glial tumor, based on histology, molecular, and clinical criteria concordant with the WHO Grading of Tumors of the Central Nervous System.
  • Age 3 years and older at screening visit.

Phase 1b/2 (all subjects) at screening:

  • Able to swallow and retain oral medication.
  • Willing to stop consumption of grapefruit, grapefruit juice, grapefruit hybrids, pomegranates, star fruits, pomelos, Seville oranges, or products containing juice of these fruits; and have not consumed these within 7 days before the first dose of study drug.
  • Willing and able to comply with scheduled visits, treatment plan, and laboratory tests.

Sex and /Barrier Requirements

  • Contraceptive and barrier use as well as pregnancy testing is required as appropriate for the age and sexual activity of pediatric and adult subjects and as required by local regulations.
  • Subjects can be male and female.
  • A legal guardian or caregiver must be able to accurately maintain the pediatric subject's take-home record, including items of general health.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with a FGFR1-3 selective inhibitor.
  • Known serious active infection or any systemic illness, which in the Investigator's opinion, cannot be adequately controlled with appropriate therapy or would compromise the subject's ability to tolerate the study drug.
  • Received anti-convulsant drugs that are strong inducers of (i.e., carbamazepine, phenobarbital, phenytoin) within 4 weeks before starting study treatment.
  • Currently receiving treatment with agents that are known strong and moderate inducers of CYP3A4 within 4 weeks from start of treatment or inhibitors of CYP3A4 within 1 week from start of treatment, including herbal preparations; medications which increase serum phosphorus and/or calcium concentration; use of a proton-pump inhibitors (e.g., omeprazole) within 4 days prior to start of study therapy or H2 receptor antagonists (e.g., famotidine) within 2 days prior to the start of study therapy.
  • Uncontrollable seizures.
  • Have current evidence of corneal or retinal disorder/keratopathy including, but not limited to, bullous/band keratopathy; corneal abrasion, inflammation, or ulceration; or keratoconjunctivitis, confirmed by ophthalmic examination. Subjects with asymptomatic ophthalmic conditions assessed by the Investigator to pose minimal risk for study participation may be enrolled in the study.
  • Have current evidence of endocrine alterations of calcium/phosphate homeostasis (e.g., parathyroid disorders, history of parathyroidectomy, tumor lysis, tumoral calcinosis), unless well controlled.
  • Have a history and/or current evidence of extensive tissue calcification including, but not limited to, the soft tissue, kidneys, intestine, vasculature, myocardium, and lung with the exception of calcified lymph nodes, minor pulmonary parenchymal calcifications, small renal cyst or stone calcifications, and asymptomatic coronary calcification.
  • Have impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral infigratinib (e.g., active ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection).
  • Had major surgery within 2 weeks of enrollment or not fully healed from open wound.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Infigratinib (BGJ398)

    Generic name: infigratinib. Dosage forms: 18mg and 25mg sprinkle capsules and 25mg, 75mg, 100mg capsules. Phase 1b Three dose levels escalation until RP2D is determined. Phase 2 * Pediatric patients: dose defined in the phase 1b (RP2D); * Adults: 125 mg. Frequency: once daily for 21 days in each 28-day treatment cycle. Duration: Treatment duration will last up to 26 cycles unless progression, death or unacceptable toxicity occur.

    Drug: Infigratinib

Interventions

  • Hard gelatin capsules for oral use

    Also known as: BGJ398

06

What researchers measure

Primary outcomes

  1. Phase 1b Dose Limiting Toxicity (DLT) rate

    An adverse event (AE) or abnormal laboratory value that are not clearly due to the underlying disease or extraneous causes, including those AEs and abnormal laboratory values that result in a failure to meet the criteria for re-treatment.

    Time frame: 28 days

  2. Phase 2 Objective Response Rate (ORR) by Blinded Independent Central Review (BICR)

    The proportion of subjects who achieve a confirmed complete response (CR), confirmed partial response (PR), or confirmed minor response (MR) for subjects with LGG. For other subjects, ORR is defined as proportion of subjects who achieve a confirmed CR or confirmed PR.

    Time frame: Up to 24 months

Secondary outcomes

  1. Phase 1b Pharmacokinetics (PK): Cmax

    The maximum observed plasma concentration after drug administration (defined as the 2-hour post-dose concentration)

    Time frame: Up to 24 months

  2. Phase 1b Pharmacokinetics (PK): AUC

    Area under the plasma concentration-time curve

    Time frame: Up to 24 months

  3. Phase 1b Pharmacokinetics (PK): T1/2

    Apparent terminal Half-Life

    Time frame: Up to 24 months

  4. Phase 1b Pharmacokinetics (PK): Tmax

    Peak time

    Time frame: Up to 24 months

  5. Phase 1b Pharmacokinetics (PK): CL/F

    Apparent clearance Day1

    Time frame: Up to 24 months

  6. Phase 1b Pharmacokinetics (PK): Vz/F

    Apparent volume of distribution

    Time frame: Up to 24 months

  7. Phase 1b Best Overall Response (BOR) assessed by Investigator

    The best response recorded from the start of the study treatment until the end of treatment taking into account any requirement for confirmation.

    Time frame: Up to 24 months

  8. Phase 1b Disease Control Rate (DCR) assessed by Investigator

    The proportion of subjects with a Best Overall Response (BOR) of complete response (CR), partial response (PR), minor response (MR) or standard deviation (SD) for subjects with LGG. For other subjects, DCR is defined as the proportion of subjects with a BOR of CR, PR or SD.

    Time frame: Up to 24 months

  9. Phase 1b Objective Response Rate (ORR) assessed by Investigator

    Time frame: Up to 24 months

  10. Phase 1b Duration of Response (DOR) assessed by Investigator

    The time from first documentation of objective response (partial response (PR), complete response (CR), minor response (MR)) to first documentation of PD or death due to any cause, whichever occurs first.

    Time frame: Up to 24 months

  11. Phase 1b Time to Response (TTR) assessed by Investigator

    The time from the date of the start of the treatment to the date of the first documented objective response (partial response (PR), complete response (CR), minor response (MR)) which is subsequently confirmed.

    Time frame: Up to 24 months

  12. Phase 1b Progression Free Survival (PFS) assessed by Investigator

    The time from the date of the start of treatment to the date of the first documented progression or death due to any cause, whichever is earlier.

    Time frame: Up to 24 months

  13. Post-treatment termination Phase 1b Progression Free Survival (PFS) assessed by Investigator

    PFS after treatment termination is the time from the date of treatment interruption for any reason excluding progression disease (PD) to the date of the first documented progression or death due to any cause, whichever is earlier.

    Time frame: After treatment termination up to progression disease (PD), assessed for further 24 months

  14. Phase 1b Best change in tumor size assessed by Investigator

    The minimum change from baseline in the sum of diameters of target lesions.

    Time frame: Up to 24 months

  15. Phase 2 Duration of Response (DOR) assessed by blinded independent central review (BICR)

    Time frame: Up to 24 months

  16. Phase 2 Time to Response (TTR) assessed by blinded independent central review (BICR)

    Time frame: Up to 24 months

  17. Phase 2 Progression Free survival (PFS) assessed by blinded independent central review (BICR)

    Time frame: 6 months from treatment initiation

  18. Phase 2 Progression Free survival (PFS) assessed by blinded independent central review (BICR)

    Time frame: 12 months from treatment initiation

  19. Phase 2 Progression Free survival (PFS) assessed by blinded independent central review (BICR)

    Time frame: 24 months from treatment initiation

  20. Post-treatment termination Phase 2 Progression Free survival (PFS) assessed by blinded independent central review (BICR)

    Time frame: After treatment termination up to progression disease (PD), assessed for further 24 months

  21. Phase 2 Overall Survival (OS)

    Overall Survival (OS) is defined as the time from the date of start of treatment to the date of death due to any cause.

    Time frame: 12 months

  22. Phase 2 Overall Survival (OS)

    Time frame: 24 months

  23. Phase 2 Best Overall Response (BOR) assessed by blinded independent central review (BICR)

    Time frame: Up to 24 months

  24. Phase 2 Disease Control Rate (DCR) assessed by blinded independent central review (BICR)

    Time frame: Up to 24 months

  25. Phase 2 Best change in tumor size assessed by blinded independent central review (BICR)

    Time frame: Up to 24 months

  26. Phase 2 Best Overall Response (BOR) assessed by Investigator

    Time frame: Up to 24 months

  27. Phase 2 Disease Control Rate (DCR) assessed by Investigator

    Time frame: Up to 24 months

  28. Phase 2 Objective Response Rate (ORR) assessed by Investigator

    Time frame: Up to 24 months

  29. Phase 2 Duration of Response (DOR) assessed by Investigator

    Time frame: Up to 24 months

  30. Phase 2 Time to Response (TTR) assessed by Investigator

    Time frame: Up to 24 months

  31. Phase 2 Progression Free Survival (PFS) assessed by Investigator

    Time frame: Up to 24 months

  32. Phase 2 Best change in tumor size assessed by Investigator

    Time frame: Up to 24 months

  33. Post-treatment termination Phase 2 Progression Free Survival (PFS) assessed by Investigator

    Time frame: After treatment termination up to progression disease (PD), assessed for further 24 months

  34. Phase 1b Incidence/severity of Adverse Events (AEs)

    Number of patients who experienced AEs to assess the safety and tolerability of infigratinib in subjects with recurrent or progressive LGG.

    Time frame: Up to 30 days after treatment termination

  35. Phase 2 Incidence/severity of Adverse Events (AEs)

    Time frame: Up to 30 days after treatment termination

  36. Phase 1b Incidence/severity of Serious Adverse Events (SAEs)

    Number of patients who experienced SAEs to assess the safety and tolerability of infigratinib in subjects with recurrent or progressive LGG.

    Time frame: Up to 30 days after treatment termination

  37. Phase 2 Incidence/severity of Serious Adverse Events (SAEs)

    Time frame: Up to 30 days after treatment termination

07

Study locations

10 sites
  • Lucile Packard Children's Hospital at Stanford University Medical Center
    Palo Alto, California 94304, United States
  • Children's National Hospital - Brain Tumor Institute
    Washington, District of Columbia 20010-2916, United States
  • Nicklaus Children's Hospital
    Miami, Florida 33155, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Duke Cancer Institute (DCI) - The Preston Robert Tisch Brain Tumor Center
    Durham, North Carolina 27702-3624, United States
  • UPCM - Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224-1529, United States
  • University of Alberta - Stollery Children's Hospital (SCH)
    Edmonton, Alberta T6G 2B7, Canada
  • McMaster Children's Hospital (MCH)
    Hamilton, Ontario L8N 3Z5, Canada
  • University of Toronto - The Hospital for Sick Children (SickKids)
    Toronto, Ontario M5G 1X8, Canada
  • Universitaetsklinikum Heidelberg (UKHD) - Zentrum fuer Kinder- und Jugendmedizin - Klinik Kinderheilkunde III
    Heidelberg, Baden-Wuerttemberg 69120, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Dec 2022, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2022
First posted
Feb 3, 2022
StartActual
Oct 1, 2021
Primary completionActual
Dec 16, 2022
CompletionActual
Dec 16, 2022
Last update
Feb 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05222165
Collaborators
Labcorp Corporation of America Holdings, Inc
Responsible party
Sponsor
First posted
Feb 3, 2022
Start date
Oct 1, 2021
Primary completion
Dec 16, 2022
Completion
Dec 16, 2022
Last update
Feb 23, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Infigratinib

Start the discussion